The company targets cancer cells' use of CD47 as a "don't eat me" signal to evade immune detection, developing a next-generation checkpoint inhibitor designed to have high affinity for CD47 while avoiding hematologic toxicities of other CD47 blocking approaches. Evorpacept is in development as combination therapy with major pharmaceutical partners including Jazz Pharmaceuticals, Quantum Leap Healthcare, Sanofi, and academic institutions across multiple cancer types.
Cyborg Score Rationale
Recent clinical data shows biomarker-driven evidence that CD47 overexpression predicts evorpacept activity in HER2-positive gastric cancer with strong efficacy signals. However, as a pre-revenue clinical-stage company with modest cash runway, execution risk on Phase 2 trials remains high. The recent $150M financing extends runway through mid-2028 with key milestone readouts expected through 2027.
Top Insights
Biomarker validation showing CD47 overexpression predicts evorpacept response, differentiating from competitors and improving clinical strategy.
$150M capital raise (net $140.4M) extends cash runway through 1H 2028, reducing near-term financing risk.
Second pipeline candidate ALX2004 is a novel EGFR-targeted antibody-drug conjugate with Phase 1 dose-escalation ongoing in EGFR-expressing solid tumors.
Analyst consensus rates ALXO as "Strong Buy" with 12-month price target of $3.42, implying 45% upside from recent prices.
Named Competitors
CD47 Checkpoint Programs — Direct CD47 checkpoint competitor with magrolimab program
Immuno-Oncology Pipeline — CD47 modulation approach in development
Broader Immune Activation — Established checkpoint inhibitors across industry
Recent Developments
(February 2026) Q4 2025 results announced with biomarker-driven CD47 validation in gastric cancer showing 65% ORR versus 26% control
(February 2026) Completed $150M registered offering providing $140.4M net proceeds extending runway through mid-2028
(October 2025) ALX2004 ADC pipeline advancement with dual best- and first-in-class potential announced at major conferences
Open the full interactive ALX Oncology Holdings Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.